News
Praliciguat Offers No Benefit for Patients with HFpEF
Compared with placebo, praliciguat offered no benefits for patients with heart failure with preserved ejection fraction (HFpEF) and is not recommended as treatment, according to results from the phase II CAPACITY HFpEF randomized clinical trial.
Source: Physician's Weekly